GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Beneish M-Score

Molecular Partners AG (XSWX:MOLN) Beneish M-Score

: 36.91 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 36.91 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Molecular Partners AG's Beneish M-Score or its related term are showing as below:

XSWX:MOLN' s Beneish M-Score Range Over the Past 10 Years
Min: 2.75   Med: 14.02   Max: 36.91
Current: 36.91

During the past 11 years, the highest Beneish M-Score of Molecular Partners AG was 36.91. The lowest was 2.75. And the median was 14.02.


Molecular Partners AG Beneish M-Score Historical Data

The historical data trend for Molecular Partners AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 2.75 14.02 36.91

Molecular Partners AG Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.02 -1.11 4.29 13.21 36.91

Competitive Comparison

For the Biotechnology subindustry, Molecular Partners AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Beneish M-Score falls into.



Molecular Partners AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Molecular Partners AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 48.9164+0.528 * 1+0.404 * 1.0348+0.892 * 0.0371+0.115 * 0.8307
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 23.4442+4.679 * 0.010723-0.327 * 1.0664
=36.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was CHF3.08 Mil.
Revenue was 1.032 + 2.541 + 0.415 + 3.05 = CHF7.04 Mil.
Gross Profit was 1.032 + 2.541 + 0.415 + 3.05 = CHF7.04 Mil.
Total Current Assets was CHF192.46 Mil.
Total Assets was CHF198.35 Mil.
Property, Plant and Equipment(Net PPE) was CHF5.68 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF2.42 Mil.
Selling, General, & Admin. Expense(SGA) was CHF19.00 Mil.
Total Current Liabilities was CHF14.42 Mil.
Long-Term Debt & Capital Lease Obligation was CHF2.44 Mil.
Net Income was -19.78 + -11.439 + -15.987 + -14.778 = CHF-61.98 Mil.
Non Operating Income was -4.255 + 0.871 + -1.177 + -0.545 = CHF-5.11 Mil.
Cash Flow from Operations was -15.988 + -13.192 + -13.281 + -16.544 = CHF-59.01 Mil.
Total Receivables was CHF1.70 Mil.
Revenue was 2.693 + 2.337 + 11.749 + 172.778 = CHF189.56 Mil.
Gross Profit was 2.693 + 2.337 + 11.749 + 172.778 = CHF189.56 Mil.
Total Current Assets was CHF254.75 Mil.
Total Assets was CHF262.26 Mil.
Property, Plant and Equipment(Net PPE) was CHF7.24 Mil.
Depreciation, Depletion and Amortization(DDA) was CHF2.39 Mil.
Selling, General, & Admin. Expense(SGA) was CHF21.82 Mil.
Total Current Liabilities was CHF17.25 Mil.
Long-Term Debt & Capital Lease Obligation was CHF3.65 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.084 / 7.038) / (1.698 / 189.557)
=0.438193 / 0.008958
=48.9164

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(189.557 / 189.557) / (7.038 / 7.038)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (192.459 + 5.681) / 198.352) / (1 - (254.752 + 7.235) / 262.258)
=0.001069 / 0.001033
=1.0348

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7.038 / 189.557
=0.0371

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.388 / (2.388 + 7.235)) / (2.42 / (2.42 + 5.681))
=0.248155 / 0.298729
=0.8307

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.995 / 7.038) / (21.822 / 189.557)
=2.69892 / 0.115121
=23.4442

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.444 + 14.416) / 198.352) / ((3.652 + 17.251) / 262.258)
=0.085 / 0.079704
=1.0664

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-61.984 - -5.106 - -59.005) / 198.352
=0.010723

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Molecular Partners AG has a M-score of 36.91 signals that the company is likely to be a manipulator.


Molecular Partners AG Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus